Post‑COVID Resurgence of Mycoplasma pneumoniae in French Children: Hospital Burden, Risk Factors for ICU Admission, and Clinical Implications
Posted inCritical Care Infectious Diseases news Pediatrics Public Health Respiratory

Post‑COVID Resurgence of Mycoplasma pneumoniae in French Children: Hospital Burden, Risk Factors for ICU Admission, and Clinical Implications

A nationwide French multicentre cohort (ORIGAMI) documents a substantial 2023–24 paediatric hospitalisation surge from Mycoplasma pneumoniae, identifies older age, asthma, comorbidity and erythema multiforme as ICU risk factors, and highlights stewardship and surveillance priorities.
Recombinant Quadrivalent Influenza Vaccine (RIV4) Shows Non‑Inferior Immunogenicity and Acceptable Safety in 9–17‑Year‑Olds: Results of a Phase 3 Immunobridging Study
Posted inInfectious Diseases news Pediatrics

Recombinant Quadrivalent Influenza Vaccine (RIV4) Shows Non‑Inferior Immunogenicity and Acceptable Safety in 9–17‑Year‑Olds: Results of a Phase 3 Immunobridging Study

A phase 3 immunobridging study found that a single dose of recombinant quadrivalent influenza vaccine (RIV4) induced non‑inferior HAI responses in 9–17‑year‑olds vs 18–49‑year‑olds, with a comparable safety profile and fewer solicited reactions in adolescents.
Adenotonsillectomy vs Watchful Waiting in Young Children with Mild–Moderate OSA: Long-term Findings from the KATE Randomized Trial
Posted innews Otorhinolaryngology Pediatrics

Adenotonsillectomy vs Watchful Waiting in Young Children with Mild–Moderate OSA: Long-term Findings from the KATE Randomized Trial

The KATE trial (n=60) found no between-group difference in polysomnographic OAHI change after 3 years, though adenotonsillectomy improved disease-specific quality of life. Nearly 42% of watchful-waiting children later underwent surgery, suggesting watchful waiting is reasonable for selected young children with mild OSA and small tonsils but requires close follow-up.
Community Health Workers Halt Decline in Quality of Life During Transition to Adult Care for Young Adults With Sickle Cell Disease
Posted inHematology-Oncology news Pediatrics

Community Health Workers Halt Decline in Quality of Life During Transition to Adult Care for Young Adults With Sickle Cell Disease

A multicenter randomized trial found that community health worker support produced modest but durable improvements in health-related quality of life for young adults with sickle cell disease during transition to adult care, whereas a mobile health intervention provided transient benefit.
Metformin Moderately Reduces Antipsychotic-Related Weight Gain in Youth with Bipolar Spectrum Disorders: Large Pragmatic 24‑Month Trial Supports Clinical Use
Posted innews Pediatrics Psychiatry

Metformin Moderately Reduces Antipsychotic-Related Weight Gain in Youth with Bipolar Spectrum Disorders: Large Pragmatic 24‑Month Trial Supports Clinical Use

A 1,565‑participant pragmatic randomized trial shows metformin added to lifestyle counseling produced modest but statistically significant reductions in BMI Z-score at 6 and 24 months in overweight/obese children and adolescents with bipolar spectrum disorders taking second‑generation antipsychotics.
Metformin Modestly Reduces Antipsychotic-Associated Weight Gain in Youth with Bipolar Spectrum Disorders — Large Pragmatic Trial Supports Consideration in Practice
Posted innews Pediatrics Psychiatry

Metformin Modestly Reduces Antipsychotic-Associated Weight Gain in Youth with Bipolar Spectrum Disorders — Large Pragmatic Trial Supports Consideration in Practice

A large, pragmatic randomized trial found that adjunctive metformin produced a modest but statistically significant reduction in BMI Z-score at 6 and 24 months among overweight and obese youth with bipolar spectrum disorders treated with second-generation antipsychotics.
CPX‑351 in Down Syndrome–Associated Myeloid Leukemia: a dose‑sensitivity mismatch that reduced event‑free survival in the ML‑DS 2018 trial
Posted inHematology-Oncology news Pediatrics

CPX‑351 in Down Syndrome–Associated Myeloid Leukemia: a dose‑sensitivity mismatch that reduced event‑free survival in the ML‑DS 2018 trial

In the ML‑DS 2018 trial, substituting reduced‑intensity induction with CPX‑351 led to lower 24‑month event‑free survival (69% vs 90%) despite excellent overall survival and minimal treatment‑related mortality; MRD by GATA1 NGS, trisomy 8 and complex karyotype predicted relapse.
Once‑Daily Dolutegravir/Lamivudine Fixed‑Dose Tablets Achieve Robust Pediatric Exposures and Reassuring Safety in the D3/PENTA 21 PK Sub‑Study
Posted inHIV/AIDS news Pediatrics

Once‑Daily Dolutegravir/Lamivudine Fixed‑Dose Tablets Achieve Robust Pediatric Exposures and Reassuring Safety in the D3/PENTA 21 PK Sub‑Study

A nested PK and safety sub‑study of D3/PENTA 21 shows once‑daily DTG/3TC dispersible and film‑coated fixed‑dose tablets deliver adequate drug exposures across WHO weight bands in children 2–<15 years, with no drug‑related discontinuations and comparable PK to historical pediatric data.